Griffiths Alys W, Albertyn Christopher P, Burnley Natasha L, Creese Byron, Walwyn Rebecca, Holloway Ivana, Safarikova Jana, Surr Claire A
Int Psychogeriatr. 2020 Feb;32(2):287. doi: 10.1017/S104161021900053X. Epub 2019 Jul 2.
The above article (Griffiths et al., 2019) published with an incorrect abstract.The correct abstract is as follows.
Behaviours associated with agitation are common in people living with dementia. The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item scale widely used to assess agitation completed by a proxy (family carer or staff member). However, proxy informants introduce possible reporting bias when blinding to the treatment arm is not possible, and potential accuracy issues due to irregular contact between the proxy and the person with dementia over the reporting period. An observational measure completed by a blinded researcher may address these issues, but no agitation measures with comparable items exist.
Development and validation of an observational version of the CMAI (CMAI-O), to assess its validity as an alternative or complementary measure of agitation.
Fifty care homes in England.
Residents (N = 726) with dementia.
Two observational measures (CMAI-O and PAS) were completed by an independent researcher. Measures of agitation, functional status, and neuropsychiatric symptoms were completed with staff proxies.
The CMAI-O showed adequate internal consistency (α = .61), criterion validity with the PAS (r = .79, p = < .001), incremental validity in predicting quality of life beyond the Functional Assessment Staging of Alzheimer's disease (β = 1.83, p < .001 at baseline) and discriminant validity from the Neuropsychiatric Inventory Apathy subscale (r = .004, p = .902).
The CMAI-O is a promising research tool for independently measuring agitation in people with dementia in care homes. Its use alongside the CMAI could provide a more robust understanding of agitation amongst residents with dementia.
上述文章(格里菲思等人,2019年)发表时摘要有误。正确摘要如下。
与激越相关的行为在痴呆症患者中很常见。科恩-曼斯菲尔德激越量表(CMAI)是一个包含29个条目的量表,广泛用于评估由代理人(家庭照顾者或工作人员)完成的激越情况。然而,当无法对治疗组进行盲法时,代理人报告可能会引入报告偏倚,并且由于在报告期内代理人与痴呆症患者之间接触不规律,还可能存在潜在的准确性问题。由不知情的研究人员完成的观察性测量可能会解决这些问题,但不存在具有可比条目的激越测量方法。
开发并验证CMAI的观察版本(CMAI-O),以评估其作为激越替代或补充测量方法的有效性。
英格兰的50家养老院。
患有痴呆症的居民(N = 726)。
由一名独立研究人员完成两项观察性测量(CMAI-O和PAS)。激越、功能状态和神经精神症状的测量由工作人员代理人完成。
CMAI-O显示出足够的内部一致性(α = 0.61),与PAS具有标准效度(r = 0.79,p = < 0.001),在预测阿尔茨海默病功能评估分期之外的生活质量方面具有增量效度(基线时β = 1.83,p < 0.001),并且与神经精神症状量表冷漠子量表具有区分效度(r = 0.004,p = 0.902)。
CMAI-O是一种很有前景的研究工具,可用于独立测量养老院中痴呆症患者的激越情况。将其与CMAI一起使用可以更全面地了解痴呆症居民中的激越情况。